Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live09-08 22:26

Amgen (AMGN) said Tuesday its phase 3 DeLLphi-305 study met its primary endpoint, with Imdelltra in combination with AstraZeneca's (AZN) Imfinzi showing a statistically significant and clinically meaningful improvement in overall survival in patients with extensive-stage small cell lung cancer.

The study evaluated the combination as first-line maintenance treatment for patients with extensive-stage small cell lung cancer whose disease had not progressed after initial treatment, Amgen said. The combination also improved progression-free survival and objective response rate, the company said.

The safety profile was consistent with the known profiles of the individual medicines, with no new or unexpected safety signals identified, the company said, adding that it plans to present detailed results at an upcoming medical congress and share the data with regulatory authorities.

Price: 402.00, Change: -35.23, Percent Change: -8.06

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment